<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A5D9C971-D5AC-42C4-858D-91D983E0B18B"><gtr:id>A5D9C971-D5AC-42C4-858D-91D983E0B18B</gtr:id><gtr:name>County Emergency Hospital, Cluj-Napoca</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4265108D-CFF2-4758-9CA3-390D816475AC"><gtr:id>4265108D-CFF2-4758-9CA3-390D816475AC</gtr:id><gtr:name>University Hospital Saarland (UKS)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:department>Institute of Life Science Medical School</gtr:department><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A5D9C971-D5AC-42C4-858D-91D983E0B18B"><gtr:id>A5D9C971-D5AC-42C4-858D-91D983E0B18B</gtr:id><gtr:name>County Emergency Hospital, Cluj-Napoca</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4265108D-CFF2-4758-9CA3-390D816475AC"><gtr:id>4265108D-CFF2-4758-9CA3-390D816475AC</gtr:id><gtr:name>University Hospital Saarland (UKS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9D47B331-1F37-45CE-A4A3-2C1747FEA65D"><gtr:id>9D47B331-1F37-45CE-A4A3-2C1747FEA65D</gtr:id><gtr:firstName>Rossen</gtr:firstName><gtr:surname>Donev</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700102"><gtr:id>E58C95ED-229A-4E67-B725-611755429F42</gtr:id><gtr:title>Modulation of expression of complement regulator CD59 in neuroblastoma as a strategy for therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700102</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Complement regulator proteins (CReg) are broadly expressed on a wide variety of tissues and cells and act as physiologic brakes to complement (C) amplification. CReg are overexpressed on a number of solid tumours as compared to the normal surrounding tissue. Consequently, the increased C resistance conferred by these membrane-bound CReg has been proposed as a mechanism that facilitates survival of the tumours. My pilot studies have investigated the mechanisms of increased resistance of neuroblastoma tumours to C-mediated lysis as a result of treatment with chemotherapeutics. I hypothesise that suppression of expression of CReg CD59 in neuroblastoma will contribute to increased susceptibility of tumours to C attack and their better immunoclearance. 

Here I propose a new strategy for the development of inhibitors of CD59. Candidate proteins up-regulating CReg in neuroblastoma cells will be identified. Recombinant prodrug proteins that activate in tumour environment and suppress expression of CD59 will be designed. Experiments to show therapeutics effect on cultured cancer cells will be performed. The most promising therapeutic agents will be tested on mouse models of human cancer. 

Goals:
1. Derive comprehensive description of the mechanisms of overexpression of CReg CD59 in neuroblastoma.
2. Design recombinant therapeutic proteins suppressing expression of CD59.
3. Characterize consequences for immunoclearance of cancer as a result of treatment with the above therapeutics combined with existing chemo- and antibody therapies.</gtr:technicalSummary><gtr:fund><gtr:end>2011-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>417213</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Saarland (UKS)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Clinic for Neurosurgery</gtr:department><gtr:description>Prof. Michael R&amp;ouml;sler</gtr:description><gtr:id>5A741B65-6A85-4687-8A85-DC72CA67C754</gtr:id><gtr:impact>Poster presented at the DGPPN meeting in Berlin 2010</gtr:impact><gtr:outcomeId>HB6M6aEsAvQ-1</gtr:outcomeId><gtr:partnerContribution>clinical samples, GWAS software and analyses</gtr:partnerContribution><gtr:piContribution>design of project; experimental analyses and discussion</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Swansea University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medicine</gtr:department><gtr:description>Dr. Jeff Davies</gtr:description><gtr:id>C23403CF-6E92-4E28-B7C4-01596576CF5C</gtr:id><gtr:impact>No papers published yet but data are currently under preparation for submission</gtr:impact><gtr:outcomeId>gmRAuzumLXm-1</gtr:outcomeId><gtr:partnerContribution>Training of staff and collaboration on a new theme.</gtr:partnerContribution><gtr:piContribution>Bringing new tehcniques to Dr. Davies reserach.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>County Emergency Hospital, Cluj-Napoca</gtr:collaboratingOrganisation><gtr:country>Romania</gtr:country><gtr:description>Dr Bogdan Voinescu</gtr:description><gtr:id>D4A7A611-3C80-49A7-A0A5-9DFE412A1C6F</gtr:id><gtr:impact>Multidisciplinary collaboration (Psychiatry and Biochemistry)
Two posters presented at international meetings.</gtr:impact><gtr:outcomeId>EAGeH5hZ5v3-1</gtr:outcomeId><gtr:partnerContribution>intellectual contribution, clinical samples</gtr:partnerContribution><gtr:piContribution>intellectual input, reagents, experimental analyses</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Swansea University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medicine</gtr:department><gtr:description>Prof. Johannes Thome</gtr:description><gtr:id>A2A6619F-1A3E-48D9-8AFA-5D8D1E4489CB</gtr:id><gtr:impact>articles PMID: 19884909; 19725918; 17353911</gtr:impact><gtr:outcomeId>EE0CD854E97-1</gtr:outcomeId><gtr:partnerContribution>intellectual input; reagents</gtr:partnerContribution><gtr:piContribution>intellectual input; reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Saarland (UKS)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Clinic for Neurosurgery</gtr:department><gtr:description>Prof. Wolfgang Retz</gtr:description><gtr:id>42F1EA61-D939-4681-828A-6A914C465F65</gtr:id><gtr:impact>A poster at the DGPPN 2010 in Berlin</gtr:impact><gtr:outcomeId>CSo5UYnX9NJ-1</gtr:outcomeId><gtr:partnerContribution>Clinical samples and intellectual contribution</gtr:partnerContribution><gtr:piContribution>intellectual contribution (design of project); experimental analyses of clinical samples</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Meeting Greece 2009</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>11CC1DA0-01D6-4C9A-9DDD-F23A605B4CC1</gtr:id><gtr:impact>An invited 25 minutes talk at the 11th International Symposium on Molecular Medicine, Crete, Greece (October 9-11, 2008). The majority of audience consisted of scientists and oncologists working on anti-tumour therapy and tumour immunology.

A number of oncologists have been convinced in the advantages of immunotherapeutic treatment of tumours and the need of finding potent adjuvants that could significantly improve patients' survival.</gtr:impact><gtr:outcomeId>CC42CF39473</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting Greece 2008</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>D389219F-2B06-4C3C-BDA2-2C8BA82AB176</gtr:id><gtr:impact>An invited 25 minutes talk at the 11th International Symposium on Molecular Medicine, Crete, Greece (October 9-11, 2008). The majority of audience consisted of scientists and oncologists working on anti-tumour therapy and tumour immunology. The data were highly appreciated. Questions and comments were on the delivery strategy I am planning to employ in order to target the REST-derived peptides to tumours.

As a result of this dissemination we had a discussion with Prof. D. Spandidos (organiser of the event) on establishing a prospective collaboration.</gtr:impact><gtr:outcomeId>7CF97D1382B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting in Berlin, Germany</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>314B8612-06F2-45E5-85D0-8F458168836D</gtr:id><gtr:impact>Around 200 health professional (mostly germans) attended the talk. A number of interesting questions on the work were discussed.

Helped to improve the study</gtr:impact><gtr:outcomeId>Pqke9HxQ58D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting in Rostock, Germany</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>823CAB5A-44E5-466A-8ABF-04BE7A2CA4A7</gtr:id><gtr:impact>Three meetings with experts in different psychiatry areas were carried out.

Set up of new collaborations.</gtr:impact><gtr:outcomeId>jHDagGMLbm1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Cardiff University</gtr:fundingOrg><gtr:id>333CE046-0C4D-4CB2-8C19-FE470CBF5795</gtr:id><gtr:outcomeId>63F6280562A0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>I have designed new peptides that target regulators of expression of CD59 gene in neuroblastoma and colorectal tumours. These peptides were proved to inhibit expression of CD59 and to increase tumour killing triggered by therapeutic monoclonal antibodies under in vitro conditions. Mechanisms leading to tumour sensitisation were identified (increased apoptosis, PBMCs killing and complement-mediated lysis, and inhibition of cancer cells proliferation). A new strategy for targeted delivery of peptide adjuvants to tumours in anti-cancer immunotherapy is under development.</gtr:description><gtr:id>00195849-77DD-4BBE-9BB9-0D95085D26C6</gtr:id><gtr:impact>This new strategy for sensitisation of tumours to immunotherapy by peptides that suppress expression of immunosuppressor genes, combined with the targeted delivery of these peptide adjuvants to tumours, would allow much more efficient killing of tumours by both innate and adaptive immunity stimulated by therapeutic antibodies.</gtr:impact><gtr:outcomeId>8FF0C40F858</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>REST68</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We found that in adult ADHD patients there are significant disturbances not only in the rhythmic secretion of endocrine factors that are key outputs and regulators of the master circadian clock, but also in circadian clock gene expression of a peripheral oscillator and in actigraphic measures of circadian organisation of gross behaviour.</gtr:description><gtr:id>AF2429A8-4421-492A-BB36-43BE469AE888</gtr:id><gtr:impact>Our study suggest that modulation of circadian rhythms may represent a novel therapeutic avenue in the management of ADHD.</gtr:impact><gtr:outcomeId>hnP94Jj6G4t</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>ADHD and clock genes</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We designed a peptide adjuvant to help increase the efficacy of anti-cancer immunotherapy by targeting the function of C/EBPb transcription factor that we found to control expression of CD46 and CD59 complement regulators. Rag2-/-gc-/-double knock-out mice (lack mature T and B cells) were injected subcutaneously with human melanoma cells transduced with either C/EBP-peptide in Lenti SxW vector or empty vector. Tumours in mice injected with the cells containing the therapeutic peptide grew much more slowly that the controls, and tumour size at the end of the experiment was 6-fold reduced compared to controls (means 39mm3 vs. 235mm3, p=0.05). We found that the therapeutic peptide promotes tumour killing in vivo mainly by the complement system.</gtr:description><gtr:id>4285CDAE-8D39-4028-BE58-CC89CC380A35</gtr:id><gtr:impact>We report for the first time involvement of C/EBP&amp;szlig; in the expression of complement regulators CD46 and CD59 which are implicated in tumor protection. Furthermore, our findings raise exciting possibilities regarding the targeting of C/EBP&amp;szlig; transcription factor and complement system in vivo as a potential therapeutic strategy for successful fighting against cancer.</gtr:impact><gtr:outcomeId>F2gGjPzGV4v</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>C/EBP-derived peptide</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A peptide derived from the neural-restrictive silencer factor (REST) was designed, named REST68, which can efficiently inhibit expression of CD59, a key protein promoting tumour growth and protecting cancer cells from complement attack.</gtr:description><gtr:id>ECAF7B6C-BAA2-48CF-A38F-65140D7C1418</gtr:id><gtr:impact>Sensitisation of tumours to antibody-based cancer immuntherapy via multiple mechanisms - enhanced apoptosis, inhibition of tumour proliferation, increased complement lysis, increased killing by PBMCs. articles PMID: 18632654; 18704229; 19025121</gtr:impact><gtr:outcomeId>025ED3E9CF2</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>REST-derived peptide; REST68</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18632654</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Patients with ADHD have significant disturbances not only in the rhythmic secretion of endocrine factors that are key outputs and regulators of the master circadian clock, but also in circadian clock gene expression of a peripheral oscillator and in actigraphic measures of circadian organisation of gross behaviour.</gtr:description><gtr:id>6A66D34E-0655-42AB-B7D5-F9DBB6C00D39</gtr:id><gtr:impact>Our data suggest that modulation of circadian rhythms may represent a novel therapeutic avenue in the management of ADHD.</gtr:impact><gtr:outcomeId>sQGo37U61aN</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ADHD and clock genes</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We described a molecular mechanism that controls expression of genes involved in cell survival and tumor growth. This mechanism applies to genes which have overlapping binding sites for neural-restrictive silencer factor (REST) and nucleolin (NCL) transcription factors within their promoters. We proposed a model for the regulation of these genes which brings a new insight into the molecular mechanisms that control cellular transformation driven by activation of protein kinases.</gtr:description><gtr:id>C3971B06-8725-4A79-8FD5-A844B29B2311</gtr:id><gtr:impact>The REST/NCL interplay model for regulation of expression of genes involved in cell survival and tumour growth enables a design of treatment for different tumor types for achieving more efficient tumor management.</gtr:impact><gtr:outcomeId>5E25837384D</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>REST/NCL interplay</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A peptide derived from the neural-restrictive silencer factor (REST) was designed, named REST5, which can efficiently enhance expression of CD59 in human neurons differentiated from progenitor cells and protect them from complement-driven neurodegeneration.</gtr:description><gtr:id>094307CA-5390-4BA8-9CA4-B60131B35769</gtr:id><gtr:impact>Protection of neurons from complement-mediated degeneration. article PMID: 19884909</gtr:impact><gtr:outcomeId>9944DC377DC</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>REST-derived peptide; REST5</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19884909</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A peptide derived from the C/EBPb transcription factor was designed, which can efficiently inhibit expression of multiple immunosuppressor genes including CD59, CD55, CD46 and CD200. Proteins encoded by these genes play key role in protecting tumours against immune system.</gtr:description><gtr:id>186B6948-2B4B-48AE-9A49-243CF629A00B</gtr:id><gtr:impact>Sensitisation of tumours to antibody-based cancer immuntherapy via multiple mechanisms - enhanced apoptosis, inhibition of tumour proliferation, increased complement lysis, increased killing by PBMCs, T cells and NK cells.</gtr:impact><gtr:outcomeId>5E17A8F0FD6</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>C/EBPb-derived peptide</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>60E9C5DA-13CA-40A4-A086-798C5991AD2C</gtr:id><gtr:title>Haloperidol alters circadian clock gene product expression in the mouse brain.</gtr:title><gtr:parentPublicationTitle>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b4f7357e31c3c822332f0f0b20df8d1"><gtr:id>1b4f7357e31c3c822332f0f0b20df8d1</gtr:id><gtr:otherNames>Coogan AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1562-2975</gtr:issn><gtr:outcomeId>NFXcu26UoY6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AB8FAF8-8DFC-4649-A50D-FE731950E60C</gtr:id><gtr:title>CD59a deficient mice display reduced B cell activity and antibody production in response to T-dependent antigens.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33a6cfd4af384fd38321f8b03bfdb5c2"><gtr:id>33a6cfd4af384fd38321f8b03bfdb5c2</gtr:id><gtr:otherNames>Sivasankar B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>4B56C382989</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>124E8A2E-E781-4455-887F-80415049EEFD</gtr:id><gtr:title>Mannan-binding lectin deficiency modulates the humoral immune response dependent on the genetic environment.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9ebfc4eb2d0b14c7bf9d98e09d0aae6"><gtr:id>c9ebfc4eb2d0b14c7bf9d98e09d0aae6</gtr:id><gtr:otherNames>Ruseva M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>sMs24XSqU4n</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8251F33B-30CC-4805-9CD4-1A1D0ECF6E7D</gtr:id><gtr:title>Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7ff36ac445a4f50de552bd38f4d5c80"><gtr:id>d7ff36ac445a4f50de552bd38f4d5c80</gtr:id><gtr:otherNames>Lancaster TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>MWJyrJpfHtg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2845D682-5402-4CE0-8D05-6F6D8F293F2B</gtr:id><gtr:title>Characterisation of different nanoparticles with a potential use for drug delivery in neuropsychiatric disorders.</gtr:title><gtr:parentPublicationTitle>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87c88040c66bbe45cd446ce2569999d3"><gtr:id>87c88040c66bbe45cd446ce2569999d3</gtr:id><gtr:otherNames>Donev R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1562-2975</gtr:issn><gtr:outcomeId>fBaPkFKVKqT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED36AD08-7798-4A92-BF5F-A5E8B4281C4F</gtr:id><gtr:title>Polymorphisms in mannan-binding lectin (MBL)-associated serine protease 2 affect stability, binding to MBL, and enzymatic activity.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e289afa0a778fbf7873826c8b18bdd5"><gtr:id>3e289afa0a778fbf7873826c8b18bdd5</gtr:id><gtr:otherNames>Thiel S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>KG5eA4BtoRj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A298BEC0-24C0-4D76-9855-C571FB5999C7</gtr:id><gtr:title>Human chromosome 1 satellite 3 DNA is decondensed, demethylated and transcribed in senescent cells and in A431 epithelial carcinoma cells.</gtr:title><gtr:parentPublicationTitle>Cytogenetic and genome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d4f87a8ba86c250ad9e0a270171bae5"><gtr:id>5d4f87a8ba86c250ad9e0a270171bae5</gtr:id><gtr:otherNames>Enukashvily NI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1424-8581</gtr:issn><gtr:outcomeId>45FA79C1847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C05EF7AC-52B2-460C-B2C8-7A3162DFB4E6</gtr:id><gtr:title>CD55 in rat male reproductive tissue: differential expression in testis and expression of a unique truncated isoform on spermatozoa.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59ff0ed464da6ffc1608861e7af956c8"><gtr:id>59ff0ed464da6ffc1608861e7af956c8</gtr:id><gtr:otherNames>Mizuno M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>6E7E22ADCA5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88FC3BA0-3E1A-48D5-B1AD-05A2DF707B7A</gtr:id><gtr:title>Comorbidity of schizophrenia and adult attention-deficit hyperactivity disorder.</gtr:title><gtr:parentPublicationTitle>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87c88040c66bbe45cd446ce2569999d3"><gtr:id>87c88040c66bbe45cd446ce2569999d3</gtr:id><gtr:otherNames>Donev R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1562-2975</gtr:issn><gtr:outcomeId>MCCTM4pJ3iQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07A6CF7D-7C08-4954-9FAE-7D0B5D3CA5CE</gtr:id><gtr:title>C3-dependent mechanism of microglial priming relevant to multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91c96941f4d2734006b4a08655721e34"><gtr:id>91c96941f4d2734006b4a08655721e34</gtr:id><gtr:otherNames>Ramaglia V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_13574_24_22219359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D41152EA-EE11-48E1-89B7-C37ED6423814</gtr:id><gtr:title>Fluoxetine treatment induces EAAT2 expression in rat brain.</gtr:title><gtr:parentPublicationTitle>Journal of neural transmission (Vienna, Austria : 1996)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77cacd6d6e5d301f328dcb7daac9de3c"><gtr:id>77cacd6d6e5d301f328dcb7daac9de3c</gtr:id><gtr:otherNames>Zink M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-9564</gtr:issn><gtr:outcomeId>TBpgVnTfiBM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BDF7773-ABFC-4518-8B0F-93D14C09A556</gtr:id><gtr:title>Nicotinic acetylcholine receptors on basophils and mast cells.</gtr:title><gtr:parentPublicationTitle>Anaesthesia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0190f780e1830818db265ad68d43d07"><gtr:id>f0190f780e1830818db265ad68d43d07</gtr:id><gtr:otherNames>Sudheer PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0003-2409</gtr:issn><gtr:outcomeId>D2DF73C7D3E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E84B5342-529D-417C-864A-ECF6E2878638</gtr:id><gtr:title>Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration.</gtr:title><gtr:parentPublicationTitle>The pharmacogenomics journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/555b586cef022502ec5a7f650dfd6225"><gtr:id>555b586cef022502ec5a7f650dfd6225</gtr:id><gtr:otherNames>Kolev MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-269X</gtr:issn><gtr:outcomeId>1F844FF5F2B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8389F988-F11A-4195-95B1-237765CD8B12</gtr:id><gtr:title>Adult attention-deficit hyperactivity disorder is associated with alterations in circadian rhythms at the behavioural, endocrine and molecular levels.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7553f1acef97f326e1e384a45a3748b0"><gtr:id>7553f1acef97f326e1e384a45a3748b0</gtr:id><gtr:otherNames>Baird AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>knw6wE6yvgH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02B4D43F-8950-489B-986C-C83996729CC4</gtr:id><gtr:title>Complement in cancer and cancer immunotherapy.</gtr:title><gtr:parentPublicationTitle>Archivum immunologiae et therapiae experimentalis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a788c06853e465636748c7f0ce3e416"><gtr:id>2a788c06853e465636748c7f0ce3e416</gtr:id><gtr:otherNames>Kolev M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0004-069X</gtr:issn><gtr:outcomeId>GaNtXoUULCR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>462D996A-2DA7-40E2-8D03-6AA26665D0E5</gtr:id><gtr:title>A role for SC35 and hnRNPA1 in the determination of amyloid precursor protein isoforms.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87c88040c66bbe45cd446ce2569999d3"><gtr:id>87c88040c66bbe45cd446ce2569999d3</gtr:id><gtr:otherNames>Donev R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>B3C02D2361F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C27BB659-D2E1-4B98-A6E7-136A4BC41DEB</gtr:id><gtr:title>Targeting transcription factors for therapeutic benefit.</gtr:title><gtr:parentPublicationTitle>Molecular bioSystems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9227456b78672ff9b7d26384062cba1"><gtr:id>e9227456b78672ff9b7d26384062cba1</gtr:id><gtr:otherNames>Brennan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1742-2051</gtr:issn><gtr:outcomeId>C0B34BF4D1D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>966E8882-082A-4C76-8AB2-8904E4F75578</gtr:id><gtr:title>Structure of human complement C8, a precursor to membrane attack.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e9b57deae404e86f13a042db157aa7e"><gtr:id>2e9b57deae404e86f13a042db157aa7e</gtr:id><gtr:otherNames>Bubeck D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>PMTdsL2LLYq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0117CD81-ED9C-4854-8546-1C0CF63A6D8D</gtr:id><gtr:title>Pilot study of the application of magnetic bead protein profiling to the study of biomarkers in addiction research.</gtr:title><gtr:parentPublicationTitle>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99c860e4b6bb89ea302f900acd7fe8cc"><gtr:id>99c860e4b6bb89ea302f900acd7fe8cc</gtr:id><gtr:otherNames>Meister L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1562-2975</gtr:issn><gtr:outcomeId>MdUXcRubb3e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>818E6D7E-4264-4F7A-8C8F-597677C9816E</gtr:id><gtr:title>Individual contributions of the aromatic chromophores to the near-UV Circular Dichroism in class A beta-lactamases: A comparative computational analysis.</gtr:title><gtr:parentPublicationTitle>Biophysical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/348fb074e2cc03d09cbd2e9284c09d85"><gtr:id>348fb074e2cc03d09cbd2e9284c09d85</gtr:id><gtr:otherNames>Karabencheva T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0301-4622</gtr:issn><gtr:outcomeId>H2LVoEM6m66</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18740812-51EC-46E7-806F-5A4C17BC6A5D</gtr:id><gtr:title>Implication of complement system and its regulators in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Current neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/555b586cef022502ec5a7f650dfd6225"><gtr:id>555b586cef022502ec5a7f650dfd6225</gtr:id><gtr:otherNames>Kolev MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1570-159X</gtr:issn><gtr:outcomeId>6B594324E00</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33423D65-A0E3-4FEA-9454-9014C6A52B8D</gtr:id><gtr:title>Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc09428a46d523e639f90f9ceaa8ea"><gtr:id>a3bc09428a46d523e639f90f9ceaa8ea</gtr:id><gtr:otherNames>Heurich B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn><gtr:outcomeId>gx8875RcB2u</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>794C04E1-63AB-4B7D-9494-879256001C87</gtr:id><gtr:title>A quantitative method for comparison of expression of alternatively spliced genes using different primer pairs.</gtr:title><gtr:parentPublicationTitle>Journal of biochemical and biophysical methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bb6b0cfa6f0d7f8dd274fdd6c42c970"><gtr:id>7bb6b0cfa6f0d7f8dd274fdd6c42c970</gtr:id><gtr:otherNames>Donev RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0165-022X</gtr:issn><gtr:outcomeId>43F05F4741C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46C23CD4-8491-4434-AB16-F3C4E7997A80</gtr:id><gtr:title>Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/945473684dac231f031deaa1e04107e3"><gtr:id>945473684dac231f031deaa1e04107e3</gtr:id><gtr:otherNames>Tediose T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>CFF51641988</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>149292EF-D9D2-41B8-A55A-1E89EDE73A64</gtr:id><gtr:title>Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e528bf290edeeb8828f680a80e6f9cb"><gtr:id>8e528bf290edeeb8828f680a80e6f9cb</gtr:id><gtr:otherNames>Ruseva MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>BC7DB45FDC5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34D328E2-EED3-430A-AB42-7842AE72C963</gtr:id><gtr:title>Neuronal death in Alzheimer's disease and therapeutic opportunities.</gtr:title><gtr:parentPublicationTitle>Journal of cellular and molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87c88040c66bbe45cd446ce2569999d3"><gtr:id>87c88040c66bbe45cd446ce2569999d3</gtr:id><gtr:otherNames>Donev R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1582-1838</gtr:issn><gtr:outcomeId>62DD6B96CF3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10D44AF8-9121-4D0D-9753-66E3BBCDCDAC</gtr:id><gtr:title>Inflammation: good or bad for ADHD?</gtr:title><gtr:parentPublicationTitle>Attention deficit and hyperactivity disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87c88040c66bbe45cd446ce2569999d3"><gtr:id>87c88040c66bbe45cd446ce2569999d3</gtr:id><gtr:otherNames>Donev R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1866-6116</gtr:issn><gtr:outcomeId>thdyMbafxUb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>681FB083-0E87-4095-BFE9-E9C9E082FE1B</gtr:id><gtr:title>The role of membrane complement regulatory proteins in cancer immunotherapy.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72a64bba4ef5acaf97f48995b3f22968"><gtr:id>72a64bba4ef5acaf97f48995b3f22968</gtr:id><gtr:otherNames>Yan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>F0F68EF1632</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700102</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>